Physician profile
Lee Yarbrough
NPI 1851509780
$11,646.79
in general payments reported to CMS, 2019-2025
38 companies · $2,750 in 2025
The $2,750 reported for 2025 was more than what 83% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,276 · 2020: $362 · 2021: $696 · 2022: $1,616 · 2023: $2,252 · 2024: $2,695 · 2025: $2,750.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,338 · Education: $360.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,337.50 |
| Education | $359.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $1,354.44 | 2021-2025 | |
| Abbvie INC. | $1,333.54 | 2019-2025 | Rinvoq, Skyrizi, Humira |
| Janssen Biotech, INC. | $1,005.67 | 2022-2025 | Tremfya, Simponi Aria, Simponi |
| Regeneron Healthcare Solutions, INC. | $787.48 | 2019-2025 | Dupixent, Libtayo |
| Sun Pharmaceutical Industries INC. | $777.77 | 2019-2025 | Ilumya, Winlevi |
| Leo Pharma INC. | $622.94 | 2019-2025 | Adbry, Anzupgo |
| Lilly USA, LLC | $599.70 | 2019-2025 | Taltz, Ebglyss, Olumiant |
| Dermavant Sciences, INC. | $580.59 | 2023-2024 | Vtama |
| Pfizer INC. | $573.98 | 2019-2025 | |
| Arcutis Biotherapeutics, INC. | $554.97 | 2023-2025 | Zoryve |
| Incyte Corporation | $498.70 | 2022-2025 | Opzelura, Opzelura |
| Novartis Pharmaceuticals Corporation | $428.92 | 2019-2025 | |
| Galderma Laboratories, L.P. | $361.62 | 2019-2025 | Nemluvio |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $316.00 | 2019-2025 | Jublia, Cabtreo, Arazlo |
| Amgen INC. | $275.54 | 2020-2025 | Otezla, Otezla, Enbrel |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $264.87 | 2019-2025 | Bimzelx |
| E.R. Squibb & Sons, L.L.C. | $217.37 | 2022-2025 | Sotyktu |
| Almirall LLC | $116.99 | 2019-2024 | Klisyri |
| Paratek Pharmaceuticals, INC. | $105.28 | 2023-2024 | Nuzyra |
| Mayne Pharma Commercial LLC | $85.40 | 2019-2023 | |
| Sanofi-Aventis U.S. LLC | $72.00 | 2021 | |
| Prugen, INC. Pharmaceuticals | $68.85 | 2019 | |
| Organon LLC | $64.33 | 2025 | Vtama |
| Vyne Pharmaceuticals INC. | $62.83 | 2020 | |
| Celgene Corporation | $62.21 | 2019 | |
| Journey Medical Corporation | $60.85 | 2022 | |
| Dermira, INC. | $59.46 | 2019-2020 | |
| Sensus Healthcare, INC. | $57.68 | 2021 | |
| Verrica Pharmaceuticals INC. | $52.19 | 2023 | Ycanth |
| Biofrontera INC. | $48.32 | 2023-2024 | Xepi, Bf-Rhodoled, Ameluz |
| Aclaris Therapeutics, INC. | $41.09 | 2019 | |
| Genentech USA, INC. | $31.16 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $24.36 | 2024 | Spevigo |
| Lnhc, INC | $23.04 | 2025 | Zelsuvmi |
| Strata Skin Sciences, INC. | $16.92 | 2024 | Xtrac |
| Botanix Sb INC | $16.28 | 2025 | Sofdra |
| Glenmark Therapeutics INC. | $12.00 | 2019 | |
| Next Science LLC | $11.45 | 2023 | Xperience, Blastx, Surgx |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lee Yarbrough listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.